These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23794116)

  • 21. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
    Gilbert JA; Miell JP; Chambers SM; McGregor AM; Aylwin SJ
    Clin Endocrinol (Oxf); 2005 Jun; 62(6):742-7. PubMed ID: 15943838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
    Pekic S; Doknic M; Miljic D; Joksimovic M; Glodic J; Djurovic M; Dieguez C; Casanueva F; Popovic V
    Eur J Endocrinol; 2006 May; 154(5):659-66. PubMed ID: 16645012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.
    Minuto F; Resmini E; Boschetti M; Arvigo M; Sormani MP; Giusti M; Ferone D; Barreca A
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):138-44. PubMed ID: 15212656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center.
    Gheorghiu ML; Găloiu S; Vintilă M; Purice M; Hortopan D; Dumitraşcu A; Coculescu M; Poiană C
    Hormones (Athens); 2016 Apr; 15(2):224-234. PubMed ID: 27376425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variable growth hormone profiles following withdrawal of long-term 30mg slow-release lanreotide treatment in acromegalic patients: clinical implications.
    Caron P; Tabarin A; Cogne M; Chanson P; Jaquet P
    Eur J Endocrinol; 2000 Jun; 142(6):565-71. PubMed ID: 10822218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands.
    Wildemberg LE; da Silva Camacho AH; Miranda RL; Elias PCL; de Castro Musolino NR; Nazato D; Jallad R; Huayllas MKP; Mota JIS; Almeida T; Portes E; Ribeiro-Oliveira A; Vilar L; Boguszewski CL; Winter Tavares AB; Nunes-Nogueira VS; Mazzuco TL; Rech CGSL; Marques NV; Chimelli L; Czepielewski M; Bronstein MD; Abucham J; de Castro M; Kasuki L; Gadelha M
    J Clin Endocrinol Metab; 2021 Jun; 106(7):2047-2056. PubMed ID: 33686418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
    Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.
    De Marinis L; Bianchi A; Fusco A; Cimino V; Mormando M; Tilaro L; Mazziotti G; Pontecorvi A; Giustina A
    Pituitary; 2007; 10(3):227-32. PubMed ID: 17484056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?
    Dobri G; Niwattisaiwong S; Bena JF; Gupta M; Kirwan J; Kennedy L; Hamrahian AH
    Endocrine; 2019 Apr; 64(1):139-146. PubMed ID: 30415402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.
    Kaltsas GA; Isidori AM; Florakis D; Trainer PJ; Camacho-Hubner C; Afshar F; Sabin I; Jenkins JP; Chew SL; Monson JP; Besser GM; Grossman AB
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1645-52. PubMed ID: 11297598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic tests and basal values for defining active acromegaly.
    Tzanela M
    Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical features and natural course of acromegaly in patients with discordance in the nadir GH level on the oral glucose test and the IGF-1 value at 3 months after adenomectomy.
    Kinoshita Y; Tominaga A; Usui S; Arita K; Sakoguchi T; Sugiyama K; Kurisu K
    Neurosurg Rev; 2016 Apr; 39(2):313-8; discussion 318-9. PubMed ID: 26785642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.
    Bacigaluppi S; Gatto F; Anania P; Bragazzi NL; Rossi DC; Benvegnu G; Nazzari E; Spaziante R; Giusti M; Ferone D; Zona G
    Endocrine; 2016 Mar; 51(3):524-33. PubMed ID: 25982150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1.
    Parfitt VJ; Flanagan D; Wood P; Leatherdale BA
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):647-52. PubMed ID: 10197081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure.
    Puig-Domingo M; Resmini E; Gomez-Anson B; Nicolau J; Mora M; Palomera E; Martí C; Halperin I; Webb SM
    J Clin Endocrinol Metab; 2010 Nov; 95(11):4973-8. PubMed ID: 20739382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
    Coopmans EC; Korevaar TIM; van Meyel SWF; Daly AF; Chanson P; Brue T; Delemer B; Hána V; Colao A; Carvalho D; Jaffrain-Rea ML; Stalla GK; Fajardo-Montañana C; Beckers A; van der Lely AJ; Petrossians P; Neggers SJCMM
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32589751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
    Cozzi R; Attanasio R; Lodrini S; Lasio G
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DISCORDANCE BETWEEN GH AND IGF-1 LEVELS IN TURKISH ACROMEGALIC PATIENTS.
    Cerit ET; Ağbaht K; Demir Ö; Şahin M; Gedik VT; Özcan C; Çorapçıoğlu D
    Endocr Pract; 2016 Dec; 22(12):1422-1428. PubMed ID: 27631850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.